BRAF and ovarian carcinoma: Our method also determined the VAF of ovarian cancer‐related sites (KRAS‐G12R, NRAS‐G12C, and BRAF‐V600E) in clinical tissue and blood samples, enabling the discrimination between ovarian cancer patients and healthy volunteers.